Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable sensor outsmart diabetic ketoacidosis?

NCT ID NCT07739342

Disease control Sponsor: Abbott Diabetes Care Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study looks at whether a wearable device that tracks both glucose and ketones can help people with type 1 diabetes avoid diabetic ketoacidosis (DKA), a serious complication. About 1,200 adults and children with type 1 diabetes will use the Abbott Continuous Dual Glucose Ketone Monitoring System instead of standard care. Researchers will track how often DKA occurs while participants manage their diabetes with this device.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Abbott Continuous Dual Glucose Ketone Monitoring System (a wearable device that continuously measures glucose and ketone levels)
What this could lead to
If successful, this device could help people with type 1 diabetes avoid dangerous episodes of diabetic ketoacidosis by alerting them early to rising ketone levels.
What could go wrong
The trial is observational, so it cannot prove the device directly prevents DKA. Results may vary by age group, and the device's accuracy and user adherence could affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Type I Diabetic patients

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged at least 2 years old at the time of study enrollment. 2. Diagnosis of type 1 diabetes with at least 12 months of diabetes medical history. 3. In the investigator's opinion, the participant is willing to wear the sensor, follow study specific instructions, and perform all study tasks. 4. Willing and able to provide written signed and dated informed consent (adults) or participant's parent/legal guardian must be willing and able to provide written signed and dated informed consent along with assent form completed by the participant for those mature enough to make their own decisions per investigator assessment (those less than 16 years of age). Exclusion Criteria: 1. In the investigator's opinion, the participant has a known (or suspected) allergy to medical grade adhesives at enrollment that would interfere with participant completing study required activities. 2. In the investigator's opinion, the participant has concomitant medical condition(s) which could interfere with the study or present a risk to the safety or welfare of the participant or study staff. 3. Participant is currently in another clinical study which may affect glucose or ketone management (or does so during the study). 4. Participant is unsuitable for participation due to any other cause as determined by the investigator. 5. Participant has implanted medical devices such as pacemakers or requires dialysis or is critically ill.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aotearoa Diabetes Collective

    Hamilton, 3204, New Zealand

  • Health New Zealand-Southern

    Dunedin, Otago, 9016, New Zealand

  • New Zealand Clinical Research

    Christchurch, Christchurch Central City, 8011, New Zealand

  • New Zealand Clinical Research

    Wellington, 6011, New Zealand

  • Optimal Clinical Trials

    Auckland, 1010, New Zealand

  • Optimal Clinical Trials (North)

    Rosedale, Auckland, 0632, New Zealand

  • Te Pae Hauora o Ruahine o Tararua /MidCentral Health New Zealand

    Palmerston North, 4414, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.